Display options
Cite
Claudino Formiga FF, Silva CA, Pedrosa TDN, et al. Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus. 2021;30(12):1915-1922doi: 10.1177/09612033211040371.
Claudino Formiga, F. F., Silva, C. A., Pedrosa, T. D. N., Aikawa, N. E., Pasoto, S. G., Garcia, C. C., Capão, A. S. V., Martins, V. A. O., Proença, A. C. T., Fuller, R., Yuki, E. F. N., Vendramini, M. B. G., Rosário, D. C. D., Brandão, L. M. K. R., Sartori, A. M. C., Antonangelo, L., Bonfá, E., & Borba, E. F. (2021). Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus, 30(12), 1915-1922. https://doi.org/10.1177/09612033211040371
Claudino Formiga, Francisco Fellipe, et al. "Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity." Lupus vol. 30,12 (2021): 1915-1922. doi: https://doi.org/10.1177/09612033211040371
Claudino Formiga FF, Silva CA, Pedrosa TDN, Aikawa NE, Pasoto SG, Garcia CC, Capão ASV, Martins VAO, Proença ACT, Fuller R, Yuki EFN, Vendramini MBG, Rosário DCD, Brandão LMKR, Sartori AMC, Antonangelo L, Bonfá E, Borba EF. Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus. 2021 Oct;30(12):1915-1922. doi: 10.1177/09612033211040371. Epub 2021 Aug 28. PMID: 34459317.
Copy Download .nbib Format: NLM
Share it on

Lupus. 2021 Oct;30(12):1915-1922. doi: 10.1177/09612033211040371. Epub 2021 Aug 28.

Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity.

Lupus

Francisco Fellipe Claudino Formiga, Clovis Artur Silva, Tatiana do Nascimento Pedrosa, Nadia Emi Aikawa, Sandra Gofinet Pasoto, Cristiana Couto Garcia, Artur Silva Vidal Capão, Victor Adriano de Oliveira Martins, Adriana Coracini Tonacio de Proença, Ricardo Fuller, Emily Figueiredo Neves Yuki, Margarete Borges Galhardo Vendramini, Debora Cordeiro do Rosário, Leticia Maria Kolachinski Raposo Brandão, Ana Marli Christovam Sartori, Leila Antonangelo, Eloisa Bonfá, Eduardo Ferreira Borba

Affiliations

  1. Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
  2. Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
  3. Laboratory of Respiratory Virus and Measles, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
  4. Department of Infectious and Parasitic Diseases, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
  5. Clinical Laboratory Division - Department of Pathology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

PMID: 34459317 DOI: 10.1177/09612033211040371

Abstract

INTRODUCTION: Influenza A (H3N2) virus is the most important cause of seasonal influenza morbidity and mortality in the last 50 years, surpassing the impact of H1N1. Data assessing immunogenicity and safety of this virus component are lacking in systemic lupus erythematosus (SLE) and restricted to small reports with other H3N2 strains.

OBJECTIVE: This study aims to evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in SLE.

METHODS: 81 consecutive SLE patients and 81 age- and sex-matched healthy controls (HC) were vaccinated with the influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers(GMT), and factor increase in GMT(FI-GMT) and adverse events were assessed before and 4 weeks post-vaccination. Disease activity and therapies were also evaluated.

RESULTS: Before immunization, SLE and HC groups had high SP rates (89% vs 77%,

CONCLUSION: Influenza A/Singapore (H3N2) vaccine has an adequate safety profile. The distinct immunogenicity pattern from other influenza A components characterized by a remarkably high pre- and post-vaccination SP rate and high GMT levels may be associated with previous influenza A vaccination. (www.clinicaltrials.gov, NCT03540823).

Keywords: H3N2; Systemic lupus erythematosus; immunogenicity; influenza; safety; vaccine

Publication Types